Peter Thompson
- Director Information, Funds, Firms
| Peter Thompson |
| Firm | OrbiMed Advisors LLC |
| Address | 601 Lexington Avenue, 54th Floor
New York, NY 10022 |
| Source |
|
| Associated Funds |
Form D |
Role |
2011 - 2026 |
Raised |
AUM |
| OrbiMed Advisors LLC |
| OrbiMed Royalty & Credit Opportunities V Offshore LP |
021-529422
|
Executive Officer |
|
1,243.5 M
of 1,750.0 M |
788.6 M |
| OrbiMed Private Investments X LP |
021-559153
|
Executive Officer |
|
of 1,750.0 M |
1,572.9 M |
| OrbiMed Royalty & Credit Opportunities V LP |
021-529419
|
Executive Officer |
|
1,243.5 M
of 1,750.0 M |
1,128.1 M |
| OrbiMed Royalty & Credit Opportunities IV Offshore LP |
021-452404
|
Executive Officer |
|
344.5 M
of 500.0 M |
567.9 M |
| OrbiMed Private Investments IX LP |
021-443751
|
Executive Officer |
|
1,849.5 M
of 1,900.0 M |
2,190.7 M |
| OrbiMed Royalty & Credit Opportunities IV LP |
021-443752
|
Executive Officer |
|
1,153.1 M
of 1,750.0 M |
1,417.7 M |
| OrbiMed Genesis Master Fund LP |
021-355430
|
Executive Officer |
|
353.3 M |
747.0 M |
| OrbiMed Partners II LP |
021-128771
|
Executive Officer |
|
1,779.5 M |
2,096.0 M |
|
| Recode Therapeutics Inc |
021-561915
|
Director |
|
29.4 M
of 29.4 M |
|
| Sparrow Pharmaceuticals Inc |
021-550457
|
Director |
|
61.8 M
of 121.4 M |
|
| Alpheus Medical Inc |
021-546462
|
Director |
|
34.5 M
of 60.5 M |
|
| Sparrow Pharmaceuticals Inc |
021-510516
|
Director |
|
10.0 M
of 15.3 M |
|
| Gennao Bio Inc |
021-466966
|
Director |
|
15.0 M
of 40.0 M |
|
| Alpheus Medical Inc |
021-464407
|
Director |
|
14.0 M
of 14.0 M |
|
| Recode Therapeutics Inc |
021-418416
|
Director |
|
259.8 M
of 290.0 M |
|
| Alpine Immune Sciences Inc |
021-415077
|
Director |
|
91.0 M
of 91.0 M |
|
| RVA Entertainment Holdings LLC |
021-401699
|
Executive Officer |
|
of 11.5 M |
|
| Sparrow Pharmaceuticals Inc |
021-386188
|
Director |
|
1.1 M
of 50.8 M |
|
| Craniovation Inc |
021-384225
|
Director |
|
6.0 M
of 16.0 M |
|
| Edgewise Therapeutics Inc |
021-382855
|
Director |
|
95.0 M
of 95.0 M |
|
| Decibel Therapeutics Inc |
021-380289
|
Director |
|
54.8 M
of 82.2 M |
|
| Silverback Therapeutics Inc |
021-377225
|
Director |
|
85.0 M
of 85.0 M |
|
| Escape Bio Inc |
021-376482
|
Director |
|
73.0 M
of 73.0 M |
|
| Alpine Immune Sciences Inc |
021-372783
|
Director |
|
60.0 M
of 82.7 M |
|
| OrbiMed New Horizons Fund LP |
021-364898
|
Executive Officer |
|
61.6 M |
|
| Recode Therapeutics Inc |
021-363315
|
Director |
|
27.5 M
of 80.0 M |
|
| Silverback Therapeutics Inc |
021-363266
|
Executive Officer |
|
31.8 M
of 78.7 M |
|
| Edgewise Therapeutics Inc |
021-349663
|
Director |
|
25.1 M
of 50.1 M |
|
| E-Scape Bio Inc |
021-345261
|
Director |
|
31.1 M
of 35.0 M |
|
| Cleave Biosciences Inc |
021-342143
|
Director |
|
12.0 M
of 20.8 M |
|
| Eqderivatives Inc |
021-340065
|
Executive Officer |
|
0.8 M
of 0.8 M |
|
| Alpine Immune Sciences Inc |
021-331755
|
Director |
|
25.3 M
of 48.7 M |
|
| Silverback Therapeutics Inc |
021-321856
|
Executive Officer |
|
12.5 M
of 20.0 M |
|
| Principia Biopharma Inc |
021-320699
|
Director |
|
50.0 M
of 50.0 M |
|
| Synthorx Inc |
021-311122
|
Director |
|
26.5 M
of 63.7 M |
|
| Prevail Therapeutics Inc |
021-307751
|
Director |
|
57.0 M
of 65.0 M |
|
| Silverback Therapeutics Inc |
021-302681
|
Executive Officer |
|
0.0 M
of 0.0 M |
|
| Alpine Immune Sciences Inc |
021-291377
|
Director |
|
17.0 M
of 17.0 M |
|
| PMV Pharmaceuticals Inc |
021-281658
|
Director |
|
73.7 M
of 73.7 M |
|
| Silverback Therapeutics Inc |
021-275309
|
Executive Officer |
|
of 0.0 M |
|
| Cleave Biosciences Inc |
021-269114
|
Director |
|
26.0 M
of 36.8 M |
|
| Alpine Immune Sciences Inc |
021-265425
|
Director |
|
10.3 M
of 48.0 M |
|
| Silverback Therapeutics Inc |
021-261100
|
Executive Officer |
|
10.0 M
of 60.0 M |
|
| Silverback Therapeutics Inc |
021-261099
|
Executive Officer |
|
0.0 M
of 0.0 M |
|
| Corvus Pharmaceuticals Inc |
021-248244
|
Director |
|
75.0 M
of 75.0 M |
|
| E-Scape Bio Inc |
021-246718
|
Director |
|
63.0 M
of 63.0 M |
|
| Principia Biopharma Inc |
021-245075
|
Director |
|
15.3 M
of 15.3 M |
|
| Corvus Pharmaceuticals Inc |
021-229629
|
Director |
|
12.7 M
of 33.5 M |
|
| Adaptimmune Ltd |
021-225667
|
Director |
|
103.8 M
of 103.8 M |
|
| Eqderivatives Inc |
021-220257
|
Executive Officer |
|
0.3 M
of 0.4 M |
|
| ProNAi Therapeutics Inc |
021-216611
|
Director |
|
59.5 M
of 59.5 M |
|
| Response Biomedical Corp |
021-204485
|
Director |
|
3.1 M
of 4.0 M |
|
| Methylgene Inc |
021-187365
|
Director |
|
26.1 M
of 35.5 M |
|
| Cardioxyl Pharmaceuticals Inc |
021-186614
|
Director |
|
28.1 M
of 28.1 M |
|
| CODA Therapeutics Inc |
021-182089
|
Director |
|
19.4 M
of 19.4 M |
|
| CODA Therapeutics Inc |
021-159761
|
Director |
|
19.2 M
of 35.0 M |
|
| Methylgene Inc |
021-158022
|
Director |
|
35.6 M
of 48.3 M |
|
| TV One LLC |
021-156584
|
Director |
|
119.0 M
of 119.0 M |
|
| Radio One Inc |
021-151499
|
Executive Officer |
|
286.8 M
of 286.8 M |
|
| Response Biomedical Corp |
021-146354
|
Director |
|
7.7 M
of 7.7 M |
|
| Trubion Pharmaceuticals Inc |
021-67751
|
Executive Officer |
|
10.0 M
of 10.0 M |
|
{"search": "/search", "clicked": "/clicked", "portfolio_add": "/portfolio-add", "portfolio_remove": "/portfolio-remove", "portfolio_create": "/portfolio-create", "portfolio_activate": "/portfolio-activate", "portfolio_delete": "/portfolio-delete", "portfolio_rename": "/portfolio-rename", "portfolio_color": "/portfolio-color", "home_filter": "/home-filter", "htmlspeed": "/htmlspeed", "add_tag_firm": "/add-tag-firm", "add_tag_click": "/add-tag-click", "copy_aum": "/copy-aum", "stripe_checkout": "/stripe-checkout", "stripe_subscribe": "/stripe-subscribe", "update_card": "/update-card"}
{"uid": 218199089, "pid": -1, "pid_a": [], "name": "", "email": "", "blacklist_f": false, "paywall_f": false, "paywall_n": 0, "random_n": 0}
False
327587810